AADI - Aadi Bioscience CEO Brendan Delaney resigns

• Aadi Bioscience ( NASDAQ: AADI ) announces that Brendan Delaney has resigned for personal reasons from his position as CEO, President, and member of the Board of Directors of the Company.
• Scott Giacobello, currently the Company's CFO, has been appointed to serve as Interim CEO and President in addition to his current responsibilities.
• Search for for a replacement CEO is underway.
• Prior to joining Aadi in 2021, Mr. Giacobello held position of CFO at at GW Pharmaceuticals, before being acquired by Jazz Pharmaceuticals in 2021. He had previously served as the CFO of Chase Pharmaceuticals prior to their acquisition by Allergan, where he served in executive roles in corporate finance and global research and development.

For further details see: